¹**Diversity of** *CFTR* **variants across ancestries characterized using 454,727 UK** ²**biobank whole exome sequences**

4 4 Justin E. Ideozu¹, Mengzhen Liu², Bridget M. Riley-Gillis², Sri R. Paladugu², Fedik Rahimov²,
5 Preethi Krishnan³ Rakesh Tripathi³ Patrick Dorr³ Hara Levy⁴ Ashyani Singh⁵ Jeffery E 5 Preethi Krishnan³, Rakesh Tripathi³, Patrick Dorr³, Hara Levy⁴, Ashvani Singh⁵, Jeffery F.
6 Waring^{1,2} and Anarna Vasanthakumar¹

- 6 Waring^{1,2}, and Aparna Vasanthakumar¹.
-
- 8 ¹ Genomic Medicine, Genomics Research Center, AbbVie, IL.
9 ² Human Genetics, Genomics Research Center, AbbVie, IL.
- 9 $\frac{2}{3}$ Human Genetics, Genomics Research Center, AbbVie, IL.
0 $\frac{3}{3}$ Precision Medicine, AbbVie, II
- 10 3 Precision Medicine, AbbVie, IL.
11 4 Department of Pediatrics Div
- ⁴ 11 ⁴ Department of Pediatrics, Division of Pulmonology and Sleep Medicine, University of Wisconsin School of Medicine and Public Health WI
- 12 Wisconsin School of Medicine and Public Health, WI.
13 ⁵Discovery Research, AbbVie. IL. 5 Discovery Research, AbbVie, IL.
- 14
15
- 15 **Keywords:** CFTR, whole exome sequencing, UK biobank, cystic fibrosis 16
-

17 ¹⁷**Abstract**

18 19 Limited understanding of the diversity of *CFTR* variants across ancestries hampers efforts to
20 advance molecular diagnosis of cystic fibrosis (CF). The consequences pose a risk of delayed 20 advance molecular diagnosis of cystic fibrosis (CF). The consequences pose a risk of delayed
21 diagnoses and subsequently worsened health outcomes for patients. Characterizing the 21 diagnoses and subsequently worsened health outcomes for patients. Characterizing the distribution of *CFTR* variants across ancestries is, therefore, critical for revolutionizing 22 distribution of *CFTR* variants across ancestries is, therefore, critical for revolutionizing
23 molecular diagnoses of CF. By interrogating 454.727 UK biobank whole exome Sequences, we 23 molecular diagnoses of CF. By interrogating 454,727 UK biobank whole exome Sequences, we
24 detected over 4,000 CFTR variants, including novel ancestry-specific variants, across six 24 detected over 4,000 *CFTR* variants, including novel ancestry-specific variants, across six
25 ancestries. F508del was the most prevalent CF-causing variant found across the ancestries. 25 ancestries. F508del was the most prevalent CF-causing variant found across the ancestries,
26 except in East Asia, where V520F was the most prevalent. Sixteen participants had two CF-26 except in East Asia, where V520F was the most prevalent. Sixteen participants had two CF-
27 causing variants, with two diagnosed as CF. We found 154 participants with a CF-causing and 27 causing variants, with two diagnosed as CF. We found 154 participants with a CF-causing and
28 varying clinical consequences (VCC) variant. Overall, participants with multiple clinically 28 varying clinical consequences (VCC) variant. Overall, participants with multiple clinically
29 relevant variants reported indications significantly associated with CF and its pulmonary 29 relevant variants reported indications significantly associated with CF and its pulmonary
20 phenotypes [Bonferroni adjusted $p<0.05$]. Potentially, participants with classical CF phenotypes 30 phenotypes [Bonferroni adjusted p<0.05]. Potentially, participants with classical CF phenotypes may benefit from current CF therapies. 31 may benefit from current CF therapies.
32

32 ³³**Introduction**

35 35 In cystic fibrosis (CF), pathogenic variants in the cystic fibrosis transmembrane conductance
36 regulator (CFTR) gene results in system-wide debilitating consequences¹. Current CFTR regulator (*CFTR*) gene results in system-wide debilitating consequences¹. Current CFTR
37 modulator therapies targeting the basic CFTR defects have yielded both short- and long-term 37 modulator therapies targeting the basic CFTR defects have yielded both short- and long-term
38 clinical benefits, but they are approved only for patients with certain CFTR variants^{2,3}. Even clinical benefits, but they are approved only for patients with certain *CFTR* variants^{2,3}. Even
39. within these patients, the response to current CFTR modulator therapies can be variable. Recent 39 within these patients, the response to current CFTR modulator therapies can be variable. Recent 40 advances in genetic technologies have led to the discovery of many CF-causing variants among 40 advances in genetic technologies have led to the discovery of many CF-causing variants among
41 populations of European ancestry. Although these findings have led to a better understanding of 41 populations of European ancestry. Although these findings have led to a better understanding of the disease prevalence, and improved diagnoses⁴, there is limited knowledge about the the disease prevalence, and improved diagnoses⁴, there is limited knowledge about the distribution of ancestry-specific *CFTR* variants. Characterizing the broad spectrum of pathogenic 43 distribution of ancestry-specific *CFTR* variants. Characterizing the broad spectrum of pathogenic
44 and non-pathogenic *CFTR* variants across ancestries holds promise to revolutionize molecular 44 and non-pathogenic *CFTR* variants across ancestries holds promise to revolutionize molecular diagnoses of CF and could enable wider access to personalized CFTR modulator therapies. 45 diagnoses of CF and could enable wider access to personalized CFTR modulator therapies.
46

47 Most studies that have surveyed the diversity of *CFTR* variants have largely focused on studying
48 nersons with CE from European populations^{5,6} This is perhans driven by the fact that CE 48 persons with CF from European populations^{5,6}. This is perhaps driven by the fact that CF predominantly affects individuals from European ancestry and the disease is less frequent in 49 predominantly affects individuals from European ancestry, and the disease is less frequent in
50 people from other ancestries. Survey reports from a diverse US population shows CF affects 50 people from other ancestries. Survey reports from a diverse US population shows CF affects
51 individuals of European ancestry (1:3000 live birth) relative to people from other ethnicities, 51 individuals of European ancestry (1:3000 live birth) relative to people from other ethnicities,
52 including Africans (1:15000), Asians (1:35,000), and Native Americans (1:10,900)^{7,8}. Globally, including Africans (1:15000), Asians (1:35,000), and Native Americans (1:10,900)^{7,8}. Globally,
53. CF is presumed to affect about 100.000 people and F508del accounts for most of the cases^{6,9}. CF is presumed to affect about 100,000 people and F508del accounts for most of the cases^{6,9}.
54. Recent reports suggest the spectrum of CF-causing variants vary across ancestries and 54 Recent reports suggest the spectrum of CF-causing variants vary across ancestries and
55 countries^{7,10}. CF-causing variants commonly reported in other ethnic groups, include 55 countries^{7,10}. CF-causing variants commonly reported in other ethnic groups, include
56. 3120+1G>A (Africans)¹⁰, p.W1282X (Ashkenazim)^{6,11}, and p.G970D (Chinese)¹². Although 56 3120+1G>A (Africans)¹⁰, p.W1282X (Ashkenazim)^{6,11}, and p.G970D (Chinese)¹². Although these studies have shed insights on common CF-causing variants in non-European populations, 57 these studies have shed insights on common CF-causing variants in non-European populations,
58 carrier screening panels do not often capture the dominant CF-causing variants in some 58 carrier screening panels do not often capture the dominant CF-causing variants in some ethnicities¹³. Thus, the prevalence of the disease in other ethnicities, and worldwide, are possibly ethnicities¹³. Thus, the prevalence of the disease in other ethnicities, and worldwide, are possibly underestimated. 60 underestimated.
61

62 62 Diagnosis of CF can be based on the results of a patients' pilocarpine iontophoresis sweat test (sweat chloride ≥ 60 mmol/L) and/or molecular genetic testing (positive for up to two CF-63 (sweat chloride ≥ 60 mmol/L) and/or molecular genetic testing (positive for up to two CF-
64 causing variants)¹⁴ One of the advantages of molecular genetic testing is that it could detect both 64 causing variants)¹⁴. One of the advantages of molecular genetic testing is that it could detect both symptomatic and pre-symptomatic individuals including the potential to determine a patients' 65 symptomatic and pre-symptomatic individuals, including the potential to determine a patients'
66 eligibility for current CFTR modulator therapies. A major drawback of solo reliance on 66 eligibility for current CFTR modulator therapies. A major drawback of solo reliance on symptomatic diagnoses is that often patients are diagnosed when they are already presenting 67 symptomatic diagnoses is that often patients are diagnosed when they are already presenting symptoms, and delayed diagnosis negatively impacts the patients' health outcomes¹⁵. Early 68 symptoms, and delayed diagnosis negatively impacts the patients' health outcomes¹⁵. Early diagnosis and interventions, particularly with triple CFTR therapy, results in improved clinical 69 diagnosis and interventions, particularly with triple CFTR therapy, results in improved clinical outcomes and could profoundly affect the trajectory of CF lung disease¹⁶. Carriers of rare 70 outcomes and could profoundly affect the trajectory of CF lung disease¹⁶. Carriers of rare
71 pathogenic variants not included in carrier screening panels are more likely to have delayed 71 pathogenic variants not included in carrier screening panels are more likely to have delayed
72 diagnosis which poses a risk of increased morbidity. Thus, it has become critical to characterize 72 diagnosis which poses a risk of increased morbidity. Thus, it has become critical to characterize
73 the broad spectrum of pathogenic *CFTR* variants across ancestral populations. 73 the broad spectrum of pathogenic *CFTR* variants across ancestral populations.
74

75 75 Determining the clinical and functional relevance of *CFTR* variants is such an inundated task that requires critical examination of the variants' impact on an individual's phenotype. This is 76 requires critical examination of the variants' impact on an individual's phenotype. This is compounded by the clinical heterogeneity often seen in patients with the same *CFTR* genotype. 77 compounded by the clinical heterogeneity often seen in patients with the same *CFTR* genotype.
78 Efforts driven by CFTR1/2 have led to the identification of 2,110 *CFTR* variants 78 Efforts driven by CFTR1/2 have led to the identification of 2,110 *CFTR* variants
79 [http://www.genet.sickkids.on.ca]. Of these, 401 are CF-causing while 49 are variants of varying 79 [http://www.genet.sickkids.on.ca]. Of these, 401 are CF-causing while 49 are variants of varying
80 clinical consequences (VCC), according to the latest CFTR2 annotation [https://cftr2.org]. The 80 clinical consequences (VCC), according to the latest CFTR2 annotation [https://cftr2.org]. The
81 CFTR1/2 databases have led to an increased understanding of CF diagnoses and prevalence 81 CFTR1/2 databases have led to an increased understanding of CF diagnoses and prevalence
82 across populations. However, the variants captured from the CFTR1/2 efforts do not necessarily 82 across populations. However, the variants captured from the CFTR1/2 efforts do not necessarily
83 represent the entirety of potential variants that could possibly exist within the *CFTR* gene across 83 represent the entirety of potential variants that could possibly exist within the *CFTR* gene across
84 ancestries. Recent annotations from TopMed Whole Genome Sequencing (WGS) efforts that 84 ancestries. Recent annotations from TopMed Whole Genome Sequencing (WGS) efforts that includes diverse populations indicate that the *CFTR* gene is about 250kb with 56,488 variants¹⁷, includes diverse populations indicate that the *CFTR* gene is about 250kb with 56,488 variants¹⁷, which is longer than the often referenced 189kb length¹⁸. Although the vast majority of these which is longer than the often referenced 189kb length¹⁸. Although the vast majority of these
87 newly detected *CFTR* variants are intronic [96%], and their clinical relevance unknown, this 87 newly detected *CFTR* variants are intronic [96%], and their clinical relevance unknown, this underscores the continued need to gain a comprehensive understanding of all pathogenic and 88 underscores the continued need to gain a comprehensive understanding of all pathogenic and
89 non-pathogenic variants that possibly exists within the *CFTR* gene, including those from various 89 non-pathogenic variants that possibly exists within the *CFTR* gene, including those from various ancestries. 90 ancestries.
91

92 The complexities associated with characterizing the clinical relevance of *CFTR* variants can be subdued by leveraging population databases, such as UK Biobank (UKBB), that hosts both 93 subdued by leveraging population databases, such as UK Biobank (UKBB), that hosts both genomics and phenotypic information of individuals. In this study, we characterized the diversity 94 genomics and phenotypic information of individuals. In this study, we characterized the diversity
95 of *CFTR* variants across six ancestral populations included in the UKBB. We segregated 95 of *CFTR* variants across six ancestral populations included in the UKBB. We segregated ancestry-specific *CFTR* variants, including those that are CF-causing from uncharacterized 96 ancestry-specific *CFTR* variants, including those that are CF-causing from uncharacterized
97 variants. We estimated the age of certain detected CF-causing variants. For participants with two 97 variants. We estimated the age of certain detected CF-causing variants. For participants with two
98 CF-causing variants or a CF-causing variant and a VCC, we performed phenotype analysis to 98 CF-causing variants or a CF-causing variant and a VCC, we performed phenotype analysis to
99 determine the possible impact of pathogenic CF-variants on their health outcomes. Our work 99 determine the possible impact of pathogenic CF-variants on their health outcomes. Our work
100 provides the foundation for future studies to explore the clinical relevance of the newly detected 100 provides the foundation for future studies to explore the clinical relevance of the newly detected 101 CFTR variants across the described ancestries. 101 *CFTR* variants across the described ancestries.
102

-
- 102 ¹⁰³**Methods**

105 ¹⁰⁵**Study population and whole exome sequences**

107 107 The dataset used for this study is available in the UKBB public repository and was accessed
108 under application 26041. A total of 454,787 UKBB whole exome sequences were interrogated to 108 under application 26041. A total of 454,787 UKBB whole exome sequences were interrogated to
109 characterize the diversity of *CFTR* variants across ancestries. The demographics and 109 characterize the diversity of *CFTR* variants across ancestries. The demographics and characteristics of the UKBB participants has been described elsewhere¹⁹, but relevant 110 characteristics of the UKBB participants has been described elsewhere¹⁹, but relevant information such as gender, age and spirometry measures were recorded for each participant. 111 information such as gender, age and spirometry measures were recorded for each participant.
112 Details on the calling and quality control can be found in previous publication¹⁹. To maximize Details on the calling and quality control can be found in previous publication¹⁹. To maximize variant discovery, no further filters were applied except the removal of individuals that 113 variant discovery, no further filters were applied except the removal of individuals that subsequently with drew consent (final $N = 454,727$). Curated disease phenotypes, defined based 114 subsequently withdrew consent (final $N = 454,727$). Curated disease phenotypes, defined based
115 on participants primary care and hospital in-patient (HESIN) records, were utilized for 115 on participants primary care and hospital in-patient (HESIN) records, were utilized for association tests with pathogenic *CFTR* genotypes. 116 association tests with pathogenic *CFTR* genotypes.
117

118 ¹¹⁸**Ancestry designation**

120 120 For ancestry designation, we opted to use the classification from the PanUKBB working group
121 (https://pan-dev.ukbb.broadinstitute.org/) which derives the ancestry classification from two 121 (https://pan-dev.ukbb.broadinstitute.org/) which derives the ancestry classification from two
122 large reference datasets, 1000 Genomes Project and Human Genome Diversity Project. Using 122 large reference datasets, 1000 Genomes Project and Human Genome Diversity Project. Using
123 this classification, the participants were grouped into six major groups: African (AFR), 123 this classification, the participants were grouped into six major groups: African (AFR), 124 American/American Admixed (AMR), Central South Asia (CSA), East Asian (EAS), European 124 American/American Admixed (AMR), Central South Asia (CSA), East Asian (EAS), European
125 (EUR), and Middle East (MID). Individuals that did not fall neatly into the large continental 125 (EUR), and Middle East (MID). Individuals that did not fall neatly into the large continental
126 classifications were classified as MIX. While this classification limits the full extent of genomic 126 classifications were classified as MIX. While this classification limits the full extent of genomic
127 diversity in the UKBB, it permitted an estimation of variant frequencies to other populations. 127 diversity in the UKBB, it permitted an estimation of variant frequencies to other populations.
128 Individuals assigned to the MIX group were included in all other counts and analysis. 128 Individuals assigned to the MIX group were included in all other counts and analysis.
129

130 ¹³⁰**Variant annotation**

131 132 Clinically relevant variants (CF-causing and VCCs) detected across the ancestries were classified
133 using CFTR2 annotation. CF-causing variants without an assigned Reference SNP cluster ID

133 using CFTR2 annotation. CF-causing variants without an assigned Reference SNP cluster ID
134 (rsID) were excluded since they comprised mostly of large indels and structural variants, which

134 (rsID) were excluded since they comprised mostly of large indels and structural variants, which
135 are often challenging to be called by variant calling tools. Functionally relevant variants (high

135 are often challenging to be called by variant calling tools. Functionally relevant variants (high intervalsed by variants (high 136 impact variants) were annotated with Variant Effect Predictor²⁰ and SnnEEE²¹ an

136 impact variants) were annotated with Variant Effect Predictor²⁰ and SnpEFF²¹ and those high
137 impact variants not known to cause CE were recorded. The canonical transcript of *CETR* 137 impact variants not known to cause CF were recorded. The canonical transcript of *CFTR*

138 (ENST00000003084) was used as reference for both tools. CF is an autosomal recessive disease
139 and molecular diagnosis could be based on the possession of two or more clinically relevant 139 and molecular diagnosis could be based on the possession of two or more clinically relevant 140 variants. Thus, participants with two CF-causing variants, a CF-causing variant and a VCC, and 140 variants. Thus, participants with two CF-causing variants, a CF-causing variant and a VCC, and 141 a CF-Causing variant and a non-CF-causing high impact variant, were characterized and 141 a CF-Causing variant and a non-CF-causing high impact variant, were characterized and
142 brioritized for further association test. Participants with two CF-causing variants were then 142 prioritized for further association test. Participants with two CF-causing variants were then
143 assigned likely disease severity status (pancreatic sufficient or insufficient) based on their *CFTR* 143 assigned likely disease severity status (pancreatic sufficient or insufficient) based on their *CFTR* genotype as previously described^{22,23}. 144 genotype as previously described^{22,23}.
145

145 ¹⁴⁶**Statistical association analysis**

148 148 We categorized participants with certain clinical or functionally relevant variant combinations
149 into three groups: two CF-causing variants, a CF-causing variant and a VCC, a CF-causing 149 into three groups: two CF-causing variants, a CF-causing variant and a VCC, a CF-causing variant and a variant of high impact. We tested each of the groups for association with disease 150 variant and a variant of high impact. We tested each of the groups for association with disease
151 phenotypes using Fisher-Exact tests. As pulmonary measures such as forced expiratory volume 151 phenotypes using Fisher-Exact tests. As pulmonary measures such as forced expiratory volume
152 (FEV) and forced vital capacity (FVC) could reflect pulmonary phenotype, we tested for 152 (FEV) and forced vital capacity (FVC) could reflect pulmonary phenotype, we tested for differences in these measures between participants with two CF-causing variants and the general 153 differences in these measures between participants with two CF-causing variants and the general population. Only associations meeting a Bonferroni corrected adjusted p-value $\langle 5\%$ were 154 population. Only associations meeting a Bonferroni corrected adjusted p-value \lt 5% were considered as statistically significant. 155 considered as statistically significant.
156

157 ¹⁵⁷**Genealogical estimation of CF-causing variants age**

158 159 To estimate the age of CF-causing variants, we used data from the Atlas of Variant Age (AVA)
160 (https://human.genome.dating/). Models using data from the 1000 Genomes Project (TGP) and 160 (https://human.genome.dating/). Models using data from the 1000 Genomes Project (TGP) and the Simons Genome Diversity Project (SGDP), implemented in the Genealogical Estimation of 161 the Simons Genome Diversity Project (SGDP), implemented in the Genealogical Estimation of Variant Age (GEVA) tool²⁴ were deployed. For variant age estimations joint mutational and 162 Variant Age (GEVA) tool²⁴, were deployed. For variant age estimations, joint mutational and recombinational clocks were considered using an average generation time of 25 years. Estimated 163 recombinational clocks were considered using an average generation time of 25 years. Estimated age of variants within the *CFTR* gene locus (Chr7: 117,095,837 – 117,366,025) were then 164 age of variants within the *CFTR* gene locus (Chr7: 117,095,837 – 117,366,025) were then reported. 165 reported.
166

- 167
- ¹⁶⁷**Result**

168 ¹⁶⁹**Over 4000** *CFTR* **variants identified across ancestries**.

170 171 We interrogated 454,787 whole exome sequences available in the UKBB to characterize the diversity of *CFTR* variants across six ancestries [AFR, CSA, EAS, EUR, AMR, and MID] and 172 diversity of *CFTR* variants across six ancestries [AFR, CSA, EAS, EUR, AMR, and MID] and an uncharacterized group (MIX). The median age across all ancestries was greater than 60 years. 173 an uncharacterized group (MIX). The median age across all ancestries was greater than 60 years.
174 Except for CSA and MID where over half of the characterized participants were males, most of 174 Except for CSA and MID where over half of the characterized participants were males, most of the ancestries were dominated by females (Table 1). Overall, we detected 4,193 variants across 175 the ancestries were dominated by females (Table 1). Overall, we detected 4,193 variants across all ancestries in the UKBB, with V470M emerging as the most common variant (Table S1). The 176 all ancestries in the UKBB, with V470M emerging as the most common variant (Table S1). The 177 CFTR variants represented a diverse range of variant types, but over 50% were intronic (Fig. 1) 177 CFTR variants represented a diverse range of variant types, but over 50% were intronic (Fig. 1)
178 The highest number of CFTR variants were detected in Europeans [n=3,192] while the AMR 178 The highest number of *CFTR* variants were detected in Europeans [n=3,192] while the AMR
179 group had the least number of *CFTR* variants [n=151]. Across the remaining ancestries [CSA, 179 group had the least number of *CFTR* variants [n=151]. Across the remaining ancestries [CSA, 180 AFR, EAS, and MID], the number of *CFTR* variants detected [471, 417, 266, and 222 180 AFR, EAS, and MID], the number of *CFTR* variants detected [471, 417, 266, and 222 respectively] were also much lower when compared to those detected in Europeans (Table 1). 181 respectively] were also much lower when compared to those detected in Europeans (Table 1).
182 Many of the variants detected in this study have never been reported as variants in *CFTR*. Next. 182 Many of the variants detected in this study have never been reported as variants in *CFTR*. Next,
183 we explored if there were *CFTR* variants uniquely represented across the ancestries. we explored if there were *CFTR* variants uniquely represented across the ancestries.

184 Interestingly, we found several *CFTR* variants that tend to be ancestry specific (Fig. 2, Table S2).
185 The highest number of unique *CFTR* variants [2212/3192] was found in Europeans, while the 185 The highest number of unique *CFTR* variants [2212/3192] was found in Europeans, while the 186 Hispanic/Admixed American group had the least number of unique *CFTR* variants [23/151]. 186 Hispanic/Admixed American group had the least number of unique *CFTR* variants [23/151].
187 About 8.3% [37850/454,727] of the overall study population did not fall under a specific 187 About 8.3% [37850/454,727] of the overall study population did not fall under a specific
188 ancestry and were categorized as the Mixed group (MIX). The median (interquartile range [IOR] 188 ancestry and were categorized as the Mixed group (MIX). The median (interquartile range [IQR] age for the MIX population was 67 (60, 67), with males accounting for 43% of the population. 189 age for the MIX population was 67 (60, 67), with males accounting for 43% of the population.
190 Within the MIX group, we detected a total of 1333 CFTR variants and 28.6% of these variants 190 Within the MIX group, we detected a total of 1333 *CFTR* variants and 28.6% of these variants 191 [n=381] were uniquely found in their population (Table 1). 191 [n=381] were uniquely found in their population (Table 1).
192

192 ¹⁹³**CF-causing variants across ancestries**

195 195 We explored the global distribution of CF-causing variants, variants of varying clinical consequences (VCC), and high impact variants. As shown in Table 2, we found varying 196 consequences (VCC), and high impact variants. As shown in Table 2, we found varying distribution of CF-causing (Table S3) and VCC (Table S4) variants across the ancestries. The 197 distribution of CF-causing (Table S3) and VCC (Table S4) variants across the ancestries. The highest number of CF-causing variants were detected in the EUR population [116/154]. These 198 highest number of CF-causing variants were detected in the EUR population [116/154]. These variants accounted for 75% of all CF-causing variants with RSIDs captured in the study. Nearly 199 variants accounted for 75% of all CF-causing variants with RSIDs captured in the study. Nearly
100 50% of the CF-causing variants were found in the MIX population, but lower proportions 200 50% of the CF-causing variants were found in the MIX population, but lower proportions 201 (<15%) were reported across the other specific ancestries. The AMR group with the least number 201 ($\lt 15\%$) were reported across the other specific ancestries. The AMR group with the least number of detected *CFTR* variants [151/4193] also had the least number [7/154] of the CF-causing 202 of detected *CFTR* variants [151/4193] also had the least number [7/154] of the CF-causing
203 variants (Table 2). F508del was the most prevalent CF-causing variant observed in all ancestries, 203 variants (Table 2). F508del was the most prevalent CF-causing variant observed in all ancestries,
204 except in EAS where V520F was the most prevalent (Fig. 3). While F508del represented ~90% 204 except in EAS where V520F was the most prevalent (Fig. 3). While F508del represented ~90% of the CF-causing variants found in Europeans, our findings indicate its prevalence was not as 205 of the CF-causing variants found in Europeans, our findings indicate its prevalence was not as
206 high in other ancestries. We further explored whether there were any CF-causing variants that 206 high in other ancestries. We further explored whether there were any CF-causing variants that were potentially ancestry-specific. As shown in Figure 4, all ancestries had unique CF-causing 207 were potentially ancestry-specific. As shown in Figure 4, all ancestries had unique CF-causing
208 variants, but EUR possessed the highest number [n=50] of ancestry-specific CF-causing variants 208 variants, but EUR possessed the highest number $[n=50]$ of ancestry-specific CF-causing variants
209 while four groups (AMR, CSA, EAS, and MID) had only one ancestry-specific variant each 209 while four groups (AMR, CSA, EAS, and MID) had only one ancestry-specific variant each 210 (Table S5). We also detected VCC variants in all ancestries [Table S4]. The number of VCC 210 (Table S5). We also detected VCC variants in all ancestries [Table S4]. The number of VCC
211 variants detected were smaller than the number of CF-causing variants detected across the 211 variants detected were smaller than the number of CF-causing variants detected across the
212 ancestries, except for AMR and MID populations. R74W was one of the most common variants 212 ancestries, except for AMR and MID populations. R74W was one of the most common variants
213 detected across the ancestries. Except for EUR, R74W featured among the top 5 most common 213 detected across the ancestries. Except for EUR, R74W featured among the top 5 most common
214 VCC reported in all ancestries. Other VCCs that made the common list included R117H, 214 VCC reported in all ancestries. Other VCCs that made the common list included R117H, 215 D1270N, and L967S (Table S6). Interestingly, we found several high impact variants that are not 215 D1270N, and L967S (Table S6). Interestingly, we found several high impact variants that are not 216 known to be CF-causing or clinically relevant in each ancestry. The highest number of these 216 known to be CF-causing or clinically relevant in each ancestry. The highest number of these
217 variants [150/200] were detected in the EUR population. Overall, high impact variants accounted 217 variants [150/200] were detected in the EUR population. Overall, high impact variants accounted
218 for only a small fraction of the total number of variants reported in each ancestry $\leq 5\%$ (Table 218 for only a small fraction of the total number of variants reported in each ancestry [\leq 5%] (Table 219 S7) and many of these [127/200] are uncharacterized in CF (Table S8). 219 S7) and many of these [127/200] are uncharacterized in CF (Table S8).
220

221 ²²¹**More than one CF-causing variants detected in participants**

222 223 With CF being an autosomal recessive disease, we explored the prevalence of participants with
224 two CF-causing variants and those heterozygous for a CF-causing variant and a VCC or high 224 two CF-causing variants and those heterozygous for a CF-causing variant and a VCC or high impact variant. We found 16 UKBB participants possessing at least two CF-causing variants 225 impact variant. We found 16 UKBB participants possessing at least two CF-causing variants 226 (Table 3). These participants were found exclusively in the CSA $[n=1]$, EUR $(n=9)$, and MIX 226 (Table 3). These participants were found exclusively in the CSA $[n=1]$, EUR (n=9), and MIX 227 $[n=6]$ populations. The CSA participant was homozygous for V456A, but various CF-causing 227 [n=6] populations. The CSA participant was homozygous for V456A, but various CF-causing
228 variant combinations were found in the EUR and MIX populations. F508del was the most 228 variant combinations were found in the EUR and MIX populations. F508del was the most
229 common CF-causing INDEL detected across the populations. Interestingly, the two individuals common CF-causing INDEL detected across the populations. Interestingly, the two individuals

230 homozygous for F508del were also diagnosed as having CF in UKBB. Many of the participants
231 with two CF-causing *CFTR* variants had combinations associated with pancreatic sufficiency 231 with two CF-causing *CFTR* variants had combinations associated with pancreatic sufficiency
232 (96%). The three variant combinations associated with pancreatic insufficiency were 232 (96%). The three variant combinations associated with pancreatic insufficiency were
233 R851X/F508del and F508del/F508del [n=2] (Table 3). We found 155 participants that harbored 233 R851X/F508del and F508del/F508del [n=2] (Table 3). We found 155 participants that harbored a CF-causing variant and a VCC (Table 4). These participants were found only in the EUR 234 a CF-causing variant and a VCC (Table 4). These participants were found only in the EUR
235 [n=145] and MIX [n=10] populations. R117H was the most reported VCC [49/154] variant in 235 [n=145] and MIX [n=10] populations. R117H was the most reported VCC [49/154] variant in the case this subset of participants, and its combination with F508del was the most common found in the 236 this subset of participants, and its combination with F508del was the most common found in the 237 EUR [38/145] and MIX [5/10] populations. L967S also featured as a common VCC variant. Its 237 EUR [38/145] and MIX [5/10] populations. L967S also featured as a common VCC variant. Its
238 combination with F508del was exclusively reported in the EUR population and dominated as the 238 combination with F508del was exclusively reported in the EUR population and dominated as the second most common combination (Table 4). Since high impact variants are potentially 239 second most common combination (Table 4). Since high impact variants are potentially functionally relevant, we assessed their distribution across the ancestries. Among the 200 high 240 functionally relevant, we assessed their distribution across the ancestries. Among the 200 high
241 impact variants detected in the participants, the highest number was found in EUR population 241 impact variants detected in the participants, the highest number was found in EUR population
242 [150/200] while the least number of these variants [4/200] were reported in both the AMR and 242 [150/200] while the least number of these variants [4/200] were reported in both the AMR and 243 EAS populations [Table S7]. We also found a high number of participants heterozygous for a 243 EAS populations [Table S7]. We also found a high number of participants heterozygous for a
244 CF-causing and high impact variant [Table S9]. These findings warranted us to interrogate the 244 CF-causing and high impact variant [Table S9]. These findings warranted us to interrogate the association of these variant with participants health outcomes. 245 association of these variant with participants health outcomes.
246

247 ²⁴⁷**Classical CF phenotypes reported in participants with two CF-causing variants and VCCs**

248 249 Phenotype analysis performed using hospital in-patient records indicated that most of the participants with at least two CF-causing variants presented classical CF phenotypes. Eight 250 participants with at least two CF-causing variants presented classical CF phenotypes. Eight $(251 - (International Classification of Diseases 10th Revision (ICD-10) codes were significantly$ 251 (International Classification of Diseases 10^{th} Revision (ICD-10) codes were significantly
252 EEDR<0.051 enriched in participants with two CE-causing variants (Fig. 5A). Specifically ICD 252 [FDR<0.05] enriched in participants with two CF-causing variants (Fig. 5A). Specifically, ICD codes directly associated with CF [E840, 848, and 849] and colonization with *Pseudomonas* 253 codes directly associated with CF [E840, 848, and 849] and colonization with *Pseudomonas*
254 *aeruginosa* [B965] were among the top significantly enriched terms. Interestingly, ICD Code 254 *aeruginosa* [B965] were among the top significantly enriched terms. Interestingly, ICD Code
255 U837 which corresponds to Resistance to Multiple Antibiotics also featured among the top 10 255 U837 which corresponds to Resistance to Multiple Antibiotics also featured among the top 10
256 enriched phenotypes. Although bronchiectasis, a classical consequence of dysfunctional CFTR, 256 enriched phenotypes. Although bronchiectasis, a classical consequence of dysfunctional CFTR,
257 was listed among the top, it did not meet our significance threshold when corrected for multiple 257 was listed among the top, it did not meet our significance threshold when corrected for multiple
258 testing (Fig. 4). With VCC variants resulting in variable clinical outcomes when combined with 258 testing (Fig. 4). With VCC variants resulting in variable clinical outcomes when combined with
259 another CF-causing variant but not often diagnosed as CF, we assessed the phenotypes of 259 another CF-causing variant but not often diagnosed as CF, we assessed the phenotypes of participants that fall within this category. Our analysis indicated that six ICD codes were 260 participants that fall within this category. Our analysis indicated that six ICD codes were
261 significantly [FDR<0.05] associated with CF [E840 and 848]; of these, pulmonary phenotypes 261 significantly [FDR<0.05] associated with CF [E840 and 848]; of these, pulmonary phenotypes [J47, B441, J998, and J440] were significantly enriched in these participants (Fig. 5B). In an 262 [J47, B441, J998, and J440] were significantly enriched in these participants (Fig. 5B). In an attempt to characterize the clinical relevance of high impact variants, we then explored the 263 attempt to characterize the clinical relevance of high impact variants, we then explored the phenotypes of participants with one CF-causing variant and a high impact variant not known to 264 phenotypes of participants with one CF-causing variant and a high impact variant not known to cause CF $(n=272)$. Surprisingly, the only significant association [FDR<0.05] returned was 265 cause CF (n=272). Surprisingly, the only significant association [FDR<0.05] returned was 266 Melanoma in situ of the trunk which is not a classical CF phenotype. Aspergillosis was featured 266 Melanoma in situ of the trunk which is not a classical CF phenotype. Aspergillosis was featured
267 among the top 10 most enriched phenotypes, but this association failed to meet our significance 267 among the top 10 most enriched phenotypes, but this association failed to meet our significance
268 threshold (Table S9). Further analysis deployed to compare differences of spirometry measures 268 threshold (Table S9). Further analysis deployed to compare differences of spirometry measures
269 (FEV1 and FVC) between participant with two CF-causing variants and the general population 269 (FEV1 and FVC) between participant with two CF-causing variants and the general population returned no significant results. 270 returned no significant results.
271

271 ²⁷²**Chronological age of CF-causing variants**

273 274 GEVA reported the estimated age of over 4,000 variants within the *CFTR* gene locus (Table 275 S10). Only four of the dated variants were CF-causing [rs139729994 (3600G>A), rs193922500 27510). Only four of the dated variants were CF-causing [rs139729994 (3600G $>$ A), rs193922500

276 (V456A), rs76713772 (1717-1G>A), rs77646904 (V520F)] (Fig. S1). The youngest variant among these, 1717-1G->A, appears to have originated \sim 425 generations ago (\sim 10,600 years) 277 among these, 1717-1G->A, appears to have originated \sim 425 generations ago (\sim 10,600 years)
278 while the earliest variant, V456A, originated about \sim 215 generations ago (\sim 5,300 years). 278 while the earliest variant, V456A, originated about \sim 215 generations ago (\sim 5,300 years).
279 Interestingly, V520F and 3600G>A which appeared \sim 338 and 270 generations ago featured 279 Interestingly, V520F and 3600G>A which appeared \sim 338 and 270 generations ago featured among the most common CF-causing variants reported in EAS population (Fig. 3). When the 280 among the most common CF-causing variants reported in EAS population (Fig. 3). When the allele frequencies of the CF-causing variants were compared with variants of similar ages within 281 allele frequencies of the CF-causing variants were compared with variants of similar ages within
282 the respective populations in AVA, there were no significant differences. Thus, an indication that 282 the respective populations in AVA, there were no significant differences. Thus, an indication that the variants were not under any selective pressure at the time of origination. 283 the variants were not under any selective pressure at the time of origination.
284

285 ²⁸⁵**Discussion**

287 287 Molecular diagnosis of CF is confounded by sparse knowledge about the prevalence of pathogenic and non-pathogenic CFTR variants across ancestries, including those that are 288 pathogenic and non-pathogenic *CFTR* variants across ancestries, including those that are potentially ancestry specific. In this study, we interrogated whole-exome sequence datasets 289 potentially ancestry specific. In this study, we interrogated whole-exome sequence datasets
290 generated from over 450, 000 UKBB participants to characterize the distribution of *CFTR* 290 generated from over 450, 000 UKBB participants to characterize the distribution of *CFTR*
291 variants across six ancestries [AFR, CSA, EAS, EUR, AMR, and MID], including an 291 variants across six ancestries [AFR, CSA, EAS, EUR, AMR, and MID], including an uncharacterized group (MIX). We report, for the first time, the detection of over 4000 CFTR 292 uncharacterized group (MIX). We report, for the first time, the detection of over 4000 *CFTR*
293 variants across the ancestries. Among the detected ancestry-specific variants were several 293 variants across the ancestries. Among the detected ancestry-specific variants were several
294 variants of clinical and functional relevance. Phenotypic characterization of participants 294 variants of clinical and functional relevance. Phenotypic characterization of participants
295 harboring multiple combinations of these variants reported indications associated with CF and its 295 harboring multiple combinations of these variants reported indications associated with CF and its
296 classical pulmonary phenotypes. 296 classical pulmonary phenotypes.
297

298 298 Although previous efforts driven by the CFTR1/2 team have led to the identification of just over
299 2000 CFTR variants within the CE population¹⁰ our report of over 4000 CFTR variants is a 2000 *CFTR* variants within the CF population¹⁰, our report of over 4000 *CFTR* variants is a
300 small fraction of potential variants that could exist within the *CFTR* gene. In silice analyses of 300 small fraction of potential variants that could exist within the *CFTR* gene. *In silico* analyses of external variant browsers such as RRAVO¹⁷ which is based on \approx 132k WGS generated by the 301 external variant browsers such as BRAVO¹⁷, which is based on ~132k WGS generated by the
302 TOPMed consortium and All of Us Research Hub²⁵ which is based on ~98k WGS and ~165k TOPMed consortium, and All of Us Research Hub²⁵, which is based on ~98k WGS and ~165k genotyping arrays reports a total of 56,448 and 39,797 *CFTR* variants, respectively. The higher 303 genotyping arrays reports a total of 56,448 and 39,797 *CFTR* variants, respectively. The higher
304 number of *CFTR* variants captured in these databases are perhaps due to WGS having the 304 number of *CFTR* variants captured in these databases are perhaps due to WGS having the capability of capturing the entire length of the *CFTR* gene while WES captures mostly exonic 305 capability of capturing the entire length of the *CFTR* gene while WES captures mostly exonic
306 regions. Overall, the vast majority of the *CFTR* variants found in UKBB [52%]. All of Us 306 regions. Overall, the vast majority of the *CFTR* variants found in UKBB [52%], All of Us 307 Research Hub [89%], and BRAVO [96%], were intronic variants. Overall, c.1408G>A (V470M 307 Research Hub [89%], and BRAVO [96%], were intronic variants. Overall, c.1408G>A (V470M
308 [rs213950]) was the most common allele (Table S1). Although in GRCH37/38 the reference 308 [rs213950]) was the most common allele (Table S1). Although in GRCH37/38 the reference
309 allele is a G, the variation associated with increased risk of chronic pancreatitis indicate at this 309 allele is a G, the variation associated with increased risk of chronic pancreatitis indicate at this $\frac{14084}{5}$ G (M470V)²⁶ Regardless a combination of this variant with another CE. 910 position is c.1408A>G (M470V)²⁶. Regardless, a combination of this variant with another CF-
311 . causing does not cause CE (https://cftr?.org), CE genetic diagnosis is largely based on 311 causing does not cause CF (https://cftr2.org). CF genetic diagnosis is largely based on 312 characterized CETR variants most of which are reported in Europeans^{4,10} Although the UKBB characterized *CFTR* variants, most of which are reported in Europeans^{4,10}. Although the UKBB
313. is dominated by people of European ancestry, which could potentially influence estimates of 313 is dominated by people of European ancestry, which could potentially influence estimates of genetic variations²⁷, CF is one of the most common life-threatening genetic disease reported in genetic variations²⁷, CF is one of the most common life-threatening genetic disease reported in this population²⁸. In line, with previous reports we also found the highest number of *CFTR* this population²⁸. In line, with previous reports we also found the highest number of *CFTR* variants in EUR population. Thus, the mutation rate of the *CFTR* gene is likely higher in the 316 variants in EUR population. Thus, the mutation rate of the *CFTR* gene is likely higher in the 317 EUR than other populations. The aspect of precision medicine for CFTR modulators is bound to 317 EUR than other populations. The aspect of precision medicine for CFTR modulators is bound to make higher impact in this CF population with such variable numbers of mutations. 318 make higher impact in this CF population with such variable numbers of mutations.
319

320 320 Many clinically (CF-causing and VCC) and functionally (High-Impact) relevant variants were
321 identified following cross-ancestry annotation of all detected variants. As their global identified following cross-ancestry annotation of all detected variants. As their global

322 distribution and frequencies are poorly understood, we characterized the most common and 323 unique CE-causing variants across populations. Indeed, like previous reports $13,29,30$ E508del was 323 unique CF-causing variants across populations. Indeed, like previous reports^{13,29,30}, F508del was
324 the most common CF-causing variant reported globally. While F508del represented ~90% of the 324 the most common CF-causing variant reported globally. While F508del represented \sim 90% of the CF-causing variants found in EUR, our findings indicate its prevalence is much lower in other 325 CF-causing variants found in EUR, our findings indicate its prevalence is much lower in other
326 populations (Fig. 3). Thus, F508del may be the maior cause of CF in EUR population, but not for 326 populations (Fig. 3). Thus, F508del may be the major cause of CF in EUR population, but not for
327 people of all ancestries. Lower frequencies of F508del in non-European populations have been 327 people of all ancestries. Lower frequencies of F508del in non-European populations have been
328 reported in several studies, and the spectrum of variants causing CF in such populations 328 reported in several studies, and the spectrum of variants causing CF in such populations 329 varies^{31,32} For example G970D has been reported as the most common cause of CF in the 329 varies^{31,32}. For example, G970D has been reported as the most common cause of CF in the 330. Chinese population¹² This variant along with V520F and 3600G>A featured among the top Chinese population¹². This variant, along with V520F and 3600G>A, featured among the top three common variants we found in the EAS group and were more common than F508del (Fig. 331 three common variants we found in the EAS group and were more common than F508del (Fig. 332 3). Although we found V520F to be the most common in EAS, it is conceivable G970D is more 332 3). Although we found V520F to be the most common in EAS, it is conceivable G970D is more common to China than V520F since the EAS group examined in this study expands beyond the 333 common to China than V520F since the EAS group examined in this study expands beyond the
334 Chinese population. Like other non-EUR populations, CF is less frequent or likely underreported 334 Chinese population. Like other non-EUR populations, CF is less frequent or likely underreported
335 in Africans¹⁰ Although E508del was the most common CE-causing variant found in the AER 335 in Africans¹⁰. Although F508del was the most common CF-causing variant found in the AFR
336. aroun 3120+1G>A which is predominantly found in Africans¹⁰ was also found to be common group, $3120+1G>A$ which is predominantly found in Africans¹⁰, was also found to be common to the AFR group (Fig. 3). Also, in South Asians, CF is thought to be less frequent. Although 337 to the AFR group (Fig. 3). Also, in South Asians, CF is thought to be less frequent. Although
338 F508del represents about 40-50% of cases, V456A the second most common CF-causing variant 338 F508del represents about 40-50% of cases, V456A the second most common CF-causing variant
339 we found in CSA (Fig.3), is a well-characterized cause of CF in South Asians^{33,34}. Some other we found in CSA (Fig.3), is a well-characterized cause of CF in South Asians^{33,34}. Some other common variants found in non-EUR populations, such as AFR (3791delC), CSA (1525-1G>A), 340 common variants found in non-EUR populations, such as AFR (3791delC), CSA (1525-1G>A), and EAS, were ancestry-specific. By comparing our findings with BRAVO reports¹⁷, we found and EAS, were ancestry-specific. By comparing our findings with BRAVO reports¹⁷, we found these variants were also rare and exclusively possessed by similar populations. Unfortunately, we 342 these variants were also rare and exclusively possessed by similar populations. Unfortunately, we found most of the common CF-causing variants found in non-European populations are not 343 found most of the common CF-causing variants found in non-European populations are not
344 included in the American College of Medical Genetics list of 23 variants recommended for CF 344 included in the American College of Medical Genetics list of 23 variants recommended for CF carrier screening³⁵. 345 carrier screening³⁵.
346

347 347 Numerous hypotheses have been put forward to explain the persistence of CF-causing variants
348 across populations, despite their detrimental impact in life outcomes. A leading hypothesis 348 across populations, despite their detrimental impact in life outcomes. A leading hypothesis postulates the heterozygous advantage of CF-causing variants against infectious diseases, such as 349 postulates the heterozygous advantage of CF-causing variants against infectious diseases, such as 350 cholera, typhoid fever, or tuberculosis³⁶. For example, the most common CF-causing variant 350 cholera, typhoid fever, or tuberculosis³⁶. For example, the most common CF-causing variant, $rs113993960$ ($FS08del$) has been estimated to have arisen approximately 600 generations 351 rs113993960 (F508del), has been estimated to have arisen approximately 600 generations
352 ago^{37,38} and its rapid increase in Europeans (MAF = 1.6%) was linked to the tuberculosis ago^{37,38} and its rapid increase in Europeans (MAF = 1.6%) was linked to the tuberculosis pandemic of the seventeenth century, against which it is thought to increase resistance in 353 pandemic of the seventeenth century, against which it is thought to increase resistance in mutation carriers³⁶. Among other variants with estimated age data in AVA, we did not detect any mutation carriers³⁶. Among other variants with estimated age data in AVA, we did not detect any variant that has rapidly increased in allele frequency as the F508del variant in Europeans. 355 variant that has rapidly increased in allele frequency as the F508del variant in Europeans.
356 Although, V520F and 3600G>A are more common CF-causing variants in EAS population than 356 Although, V520F and 3600G>A are more common CF-causing variants in EAS population than
357 F508del (Fig. 3), their allele frequencies were not significantly different from other variants of 357 F508del (Fig. 3), their allele frequencies were not significantly different from other variants of similar ages in EAS population. Thus, F508del is likely a unique variant that confers selective 358 similar ages in EAS population. Thus, F508del is likely a unique variant that confers selective
359 pressure, which has kept its frequency relatively high. 359 pressure, which has kept its frequency relatively high.
360

361 361 Beyond CF-causing variants, we also found several VCCs, and High Impact variants not known
362 to cause CF but predicted to severely impact protein function. R117H the common VCC, which 362 to cause CF but predicted to severely impact protein function. R117H the common VCC, which
363 results in reduced single-channel activity and open probability³⁹ was the most prevalent VCC results in reduced single-channel activity and open probability³⁹, was the most prevalent VCC $\frac{364}{4}$ detected across the ancestries (Table S5). Clinical manifestations of patients with R117H are 364 detected across the ancestries (Table S5). Clinical manifestations of patients with R117H are
365 heterogenous and largely influenced by its combination with another CF-causing variant or other 365 heterogenous and largely influenced by its combination with another CF-causing variant or other
366 common variants of poly-T tract (5T, 7T, and 9T). R117H-T5 is reported to potentially result in 366 common variants of poly-T tract (5T, 7T, and 9T). R117H-T5 is reported to potentially result in
367 less functional CFTR and pancreatic sufficiency when patients are homozygous for this less functional CFTR and pancreatic sufficiency when patients are homozygous for this

combination or when found in compound heterozygosity with a CF-causing variant⁴⁰. Most of the predicted High Impact variants found in our study were already known to cause CF (deduced 369 the predicted High Impact variants found in our study were already known to cause CF (deduced with the CFTR2 annotation). After excluding these variants, we still found some uncharacterized 370 with the CFTR2 annotation). After excluding these variants, we still found some uncharacterized
371 High Impact variants. Taken together, these findings indicated a handful of UKBB participants 371 High Impact variants. Taken together, these findings indicated a handful of UKBB participants
372 harbored clinically and functionally relevant *CFTR* variants. 372 harbored clinically and functionally relevant *CFTR* variants.
373

373 374 Since CF is an autosomal recessive disease, we characterized UKBB participants with more than
375 one clinical or functional relevant variant. Interestingly, we found sixteen UKBB participants 375 one clinical or functional relevant variant. Interestingly, we found sixteen UKBB participants
376 with at least two CF-causing variants. Collectively, these participants reported ICD codes 376 with at least two CF-causing variants. Collectively, these participants reported ICD codes
377 associated with classical CF phenotypes [Fig. 5A], despite the fact only two participants 377 associated with classical CF phenotypes [Fig. 5A], despite the fact only two participants
378 (F508del homozygotes) were diagnosed as CF in UKBB electronic health records. Undiagnosed 378 (F508del homozygotes) were diagnosed as CF in UKBB electronic health records. Undiagnosed cases of CF, especially in patients with milder forms of the disease caused by rare pathogenic 379 cases of CF, especially in patients with milder forms of the disease caused by rare pathogenic
380 genotypes, is not uncommon⁴¹. Most of the variant combinations reported in our findings likely genotypes, is not uncommon⁴¹. Most of the variant combinations reported in our findings likely
381 result in pancreatic sufficiency, except for one participant harboring the F508del/R851X 381 result in pancreatic sufficiency, except for one participant harboring the F508del/R851X
382 genotype that results in pancreatic insufficiency. Although the F508del/R851X participant was 382 genotype that results in pancreatic insufficiency. Although the F508del/R851X participant was not diagnosed as CF in UKBB, the retrieved ICD10 code indicated the participant suffered 383 not diagnosed as CF in UKBB, the retrieved ICD10 code indicated the participant suffered
384 majorly from Chest Pain [R074]. This variant combination, which was detected in an EUR 384 majorly from Chest Pain [R074]. This variant combination, which was detected in an EUR participant, is less common in CF, with a frequency of only ~ 0.0002 recorded in CFTR2 385 participant, is less common in CF, with a frequency of only ~ 0.0002 recorded in CFTR2 database [https://cftr2.org]. Another rarer genotype with ~ 0.00002 frequency in CFTR2 which 386 database [https://cftr2.org]. Another rarer genotype with ~ 0.00002 frequency in CFTR2 which
387 we found was V456A/V456A. This variant is known to cause CF in South Asians³³ and likewise 387 we found was V456A/V456A. This variant is known to cause CF in South Asians³³ and likewise
388 was detected in a CSA participant. Some of the detected pathogenic genotypes, such as 388 was detected in a CSA participant. Some of the detected pathogenic genotypes, such as L206W/S945L and R1066H/1154insTC, have not yet been recorded in CFTR2. Taken together, 389 L206W/S945L and R1066H/1154insTC, have not yet been recorded in CFTR2. Taken together,
390 a possible explanation for the undiagnosed cases captured in our study may be due to the 390 a possible explanation for the undiagnosed cases captured in our study may be due to the rareness of the variants and milder presentation of the disease. 391 rareness of the variants and milder presentation of the disease.
392

392 393 We recorded about 10-fold more participants harboring a CF-causing variant and a VCC, than those with two CF-causing variants (154 vs 16, respectively). VCCs contribute majorly to the 394 those with two CF-causing variants (154 vs 16, respectively). VCCs contribute majorly to the complexities associated with genetic diagnosis of CF, because clinical outcomes vary widely 395 complexities associated with genetic diagnosis of CF, because clinical outcomes vary widely
396 across patient populations⁴² For this sub-group of participants, we also found significant 396 across patient populations⁴². For this sub-group of participants, we also found significant 397 enrichment of ICD codes associated with classical CE (ICD Codes: E840 and E848) and 397 enrichment of ICD codes associated with classical CF (ICD Codes: E840 and E848) and
398 pulmonary phenotypes, including bronchiectasis, Aspergillosis, and COPD with acute lower 398 pulmonary phenotypes, including bronchiectasis, Aspergillosis, and COPD with acute lower respiratory infections. Participants with these genotypes were reported only in EUR and MIX 399 respiratory infections. Participants with these genotypes were reported only in EUR and MIX
400 populations, and the most dominant combination was F508del/R117H. This variant combination 400 populations, and the most dominant combination was F508del/R117H. This variant combination
401 on its own does not cause CF but when in *cis* with 5T ploy-Tract variant, then CF diagnosis is 401 on its own does not cause CF but when in *cis* with 5T ploy-Tract variant, then CF diagnosis is
402 likely⁴⁰. About 1,310 patients have the F508del/R117H variant combination in CFTR2 and 22% likely⁴⁰. About 1,310 patients have the F508del/R117H variant combination in CFTR2 and 22% of these are pancreatic insufficient. Meanwhile, 80 patients have the F508del/R117H;5T 403 of these are pancreatic insufficient. Meanwhile, 80 patients have the F508del/R117H;5T combination and 33% of them are pancreatic insufficient [https://cftr2.org]. Although these 404 combination and 33% of them are pancreatic insufficient [https://cftr2.org]. Although these
405 participants are not diagnosed as CF, their inclusion as patients in CFTR2 suggest they suffer the 405 participants are not diagnosed as CF, their inclusion as patients in CFTR2 suggest they suffer the
406 burden of dysfunctional CFTR. The F508del/L967S genotype, which was the second most 406 burden of dysfunctional CFTR. The F508del/L967S genotype, which was the second most common found in this subgroup (CF-causing+VCC), was rare in CFTR2. Only seven patients 407 common found in this subgroup (CF-causing+VCC), was rare in CFTR2. Only seven patients
408 had this combo and clinical outcome, though variable, is largely expected to be pancreatic 408 had this combo and clinical outcome, though variable, is largely expected to be pancreatic
409 sufficient. The identification of several UKBB participants harboring such variant combinations 409 sufficient. The identification of several UKBB participants harboring such variant combinations
410 and showing CF-like symptoms, is therefore an indication that a number of undiagnosed or 410 and showing CF-like symptoms, is therefore an indication that a number of undiagnosed or 411 unreported CF cases may benefit from modulator therapies. Additionally, we found no 411 unreported CF cases may benefit from modulator therapies. Additionally, we found no
412 differences in pulmonary measures (FEV and FVC) between participants with two CF-causing 412 differences in pulmonary measures (FEV and FVC) between participants with two CF-causing
413 variants and the general population. Given that the UKBB recruited individuals that were over 40 variants and the general population. Given that the UKBB recruited individuals that were over 40

414 years old, the individuals with multiple clinically relevant *CFTR* genotypes likely have a milder form of the disease with a different disease etiology that nevertheless could be potentially either

- 415 form of the disease with a different disease etiology that nevertheless could be potentially either
416 treated or prevented by appropriate CFTR-based interventions. 416 treated or prevented by appropriate CFTR-based interventions.
417
-

418 418 A major drawback to existing knowledge about pathogenic *CFTR* variants is that most studies
419 have been conducted in European populations. However, CF is also prevalent in people from 419 have been conducted in European populations. However, CF is also prevalent in people from
420 other ancestries, who may harbor uncharacterized unique variants⁴. Even in individuals of 420 other ancestries, who may harbor uncharacterized unique variants⁴. Even in individuals of 421 European ancestry, where most of the studies have been conducted, there are several *CFTR* European ancestry, where most of the studies have been conducted, there are several *CFTR*
422 variants with unknown clinical significance. In attempt to decipher the clinical relevance of 422 variants with unknown clinical significance. In attempt to decipher the clinical relevance of uncharacterized high impact *CFTR* variants detected across the UKBB population, we performed 423 uncharacterized high impact *CFTR* variants detected across the UKBB population, we performed
424 a phenotype analysis of participants with a CF-causing variant and a non-CF-causing 424 a phenotype analysis of participants with a CF-causing variant and a non-CF-causing (uncharacterized) high impact variant but found no interesting association. Databases such as the 425 (uncharacterized) high impact variant but found no interesting association. Databases such as the 426 UKBB offer an unprecedented opportunity to correlate uncharacterized genotype and phenotype 426 UKBB offer an unprecedented opportunity to correlate uncharacterized genotype and phenotype information at a population scale. Although we utilized the UKBB resource to characterize the 427 information at a population scale. Although we utilized the UKBB resource to characterize the ancestral diversity of *CFTR* variants, most of the participants are of European ancestry. Recent 428 ancestral diversity of *CFTR* variants, most of the participants are of European ancestry. Recent genome sequencing efforts that included more diverse populations, such as the NIH All of Us 429 genome sequencing efforts that included more diverse populations, such as the NIH All of Us
430 and ToPMed programs, report even more *CFTR* variants in comparison to UKBB. However, 430 and ToPMed programs, report even more *CFTR* variants in comparison to UKBB. However, 1431 limited access to phenotype information at an individual level makes it challenging to unravel the 431 limited access to phenotype information at an individual level makes it challenging to unravel the clinical relevance of the detected *CFTR* variants. 432 clinical relevance of the detected *CFTR* variants.
433

433 434 Here, we aimed to characterize the natural variation that exists within the *CFTR* gene that is not 435 limited to persons with CF. The large majority (>95%) of variants surveyed have allele 435 limited to persons with CF. The large majority ($>95\%$) of variants surveyed have allele frequencies less than 1% and \sim 9% of all variations are indels. While sequencing technology has 436 frequencies less than 1% and \sim 9% of all variations are indels. While sequencing technology has improved in accuracy and quality control filters have removed many of the problematic variants, 437 improved in accuracy and quality control filters have removed many of the problematic variants,
438 identification, and interpretation of novel rare variants (specifically singletons and doubletons) 438 identification, and interpretation of novel rare variants (specifically singletons and doubletons)
439 would warrant more precise methods (such as targeted sequencing) for confirmation. Another 439 would warrant more precise methods (such as targeted sequencing) for confirmation. Another 440 limitation of our study is the lack of precise CF-related phenotypes, such as FEV1% predicted 440 limitation of our study is the lack of precise CF-related phenotypes, such as FEV1% predicted
441 and sweat chloride levels in the electronic health records extracted from UKBB. Although we 441 and sweat chloride levels in the electronic health records extracted from UKBB. Although we
442 captured some spirometry measures, we lacked information relevant to deduce FEV1% scores 442 captured some spirometry measures, we lacked information relevant to deduce FEV1% scores and there were no records of sweat chloride levels for the participants. 443 and there were no records of sweat chloride levels for the participants.
444

445 445 In summary, we have leveraged the UKBB resource to comprehensively characterize the broad
446 spectrum of *CFTR* variants across ancestries. Until now, most efforts aimed at identifying and 446 spectrum of *CFTR* variants across ancestries. Until now, most efforts aimed at identifying and characterizing *CFTR* variants have focused more on surveying *CF* populations in a relatively 447 characterizing *CFTR* variants have focused more on surveying CF populations in a relatively
448 smaller sample size. For the first time, we report the detection of over 4000 *CFTR* variants, at 448 smaller sample size. For the first time, we report the detection of over 4000 *CFTR* variants, which nearly doubles the number of variants reported by CFTR1/2. However, the higher number 449 which nearly doubles the number of variants reported by CFTR1/2. However, the higher number
450 of variants reported by the NIH All of Us and ToPMed diverse sequencing programs suggests 450 of variants reported by the NIH All of Us and ToPMed diverse sequencing programs suggests
451 the 4000 CFTR variants represents only a small fraction of variants that exist in the CFTR gene. 451 the 4000 *CFTR* variants represents only a small fraction of variants that exist in the *CFTR* gene.
452 The identification of several ancestry-specific variants, including uncharacterized functionally 452 The identification of several ancestry-specific variants, including uncharacterized functionally
453 relevant variants, warrants the need for CF screening panels to consider ethnic specificities. The 453 relevant variants, warrants the need for CF screening panels to consider ethnic specificities. The presentation of classical CF phenotypes seen in some non-CF diagnosed participants, with CF-454 presentation of classical CF phenotypes seen in some non-CF diagnosed participants, with CF-
455 causing and VCC variants, indicates they may benefit from current *CFTR* therapies. As more 455 causing and VCC variants, indicates they may benefit from current *CFTR* therapies. As more
456 diverse *CFTR* sequences are becoming increasingly available in genomic databases, future 456 diverse *CFTR* sequences are becoming increasingly available in genomic databases, future studies are encouraged to leverage such resources to characterize the clinical relevance of high 457 studies are encouraged to leverage such resources to characterize the clinical relevance of high
458 impact variants not previously known to cause CF. 458 impact variants not previously known to cause CF.
459

⁴⁶⁰**Supplementary information**

462 462 Supplementary Tables 1-7: **Table S1.** Detected *CFTR* variants across UKBB populations; **Table S2.** Unique CF-causing variants; **Table S3.** CF-causing *CFTR* variants; **Table S4.** Variable ⁴⁶³**S2.** Unique CF-causing variants; **Table S3.** CF-causing *CFTR* variants; **Table S4.** Variable 464 clinical consequence variants detected across UKBB ancestries; **Table S5.** Unique CF-causing
465 variants: **Table S6.** Common varying clinical consequences (VCC) variants: **Table S7.** CFTR 465 variants; **Table S6.** Common varying clinical consequences (VCC) variants; **Table S7.** *CFTR* variants annotated as having High Impact; **Table S8.** Uncharacterized high impact variants; 466 variants annotated as having High Impact; **Table S8.** Uncharacterized high impact variants;
467 **Table S9.** High impact and CF-Causing variants. **Table S10**. Dated variants within the CFTR ⁴⁶⁷**Table S9.** High impact and CF-Causing variants. **Table S10**. Dated variants within the CFTR 468 gene locus
469 Supplemen 469 Supplementary Figures: **Figure S1**. Venn diagram showing genealogical estimation of variant 470 age (GEVA) analysis of CF-causing variants

- 470 age (GEVA) analysis of CF-causing variants 471
-

472 ⁴⁷²**Data availability**

-
- 473 474 Access to UK biobank resource is available by application (http://www.ukbiobank.ac.uk/). The 475 UK biobank exome sequences analyzed in this study were obtained under application 26401.
- 475 UK biobank exome sequences analyzed in this study were obtained under application 26401.
476
-

477 ⁴⁷⁷**Ethics declarations**

478 479 Competing interests: The authors declare no competing interest. The design, study conduct, and
480 financial support for this research were provided by AbbVie. AbbVie participated in the 480 financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. JEI, ML, BRG, SRP, FR, PK, RT, 481 interpretation of data, review, and approval of the publication. JEI, ML, BRG, SRP, FR, PK, RT, 482 PD, AS, JFW, and AV are employees of AbbVie. HL is an employee of University of Wisconsin 482 PD, AS, JFW, and AV are employees of AbbVie. HL is an employee of University of Wisconsin
483 School of Medicine and Public Health and provided her expertise on CF genetics and 483 School of Medicine and Public Health and provided her expertise on CF genetics and translational research (no funding to disclose). 484 translational research (no funding to disclose).
485

485 ⁴⁸⁶**Acknowledgement**

488 488 We would like to acknowledge and extend our gratitude to the AbbVie GRC Internal Reviewers;
489 Anneke Den Hollander and Nizar Smaoui.

- 489 Anneke Den Hollander and Nizar Smaoui.
490
-

491 ⁴⁹¹**References**

-
- 492 493 1. Raraigh, K.S. *et al.* Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment. *J Cyst Fibros* 21, 463-470 (2022). 494 fibrosis informs variant-specific treatment. *J Cyst Fibros* 21, 463-470 (2022).
495 2. Despotes, K.A. & Donaldson, S.H. Current state of CFTR modulators for t
- 495 2. Despotes, K.A. & Donaldson, S.H. Current state of CFTR modulators for treatment of Cystic Fibrosis. Curr Opin Pharmacol 65, 102239 (2022). 496 Cystic Fibrosis. *Curr Opin Pharmacol* **65**, 102239 (2022).
497 3. Griese, M. *et al.* Safety and Efficacy of Elexacaftor/Tezaca
- 497 3. Griese, M. *et al.* Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or
498 Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results 498 Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results
499 of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med 203, 381-385 499 of an Open-Label Phase 3 Clinical Trial. *Am J Respir Crit Care Med* 203, 381-385
500 (2021). $(2021).$

- 501 4. Guo, J., Garratt, A. & Hill, A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. *J Cyst Fibros* 21, 456-462 (2022). 502 cystic fibrosis. *J Cyst Fibros* 21, 456-462 (2022).
503 5. Corvol, H. *et al*. Genome-wide association meta-
- 503 5. Corvol, H. *et al.* Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. *Nat Commun* **6**, 8382 (2015). 504 lung disease severity in cystic fibrosis. *Nat Commun* **6**, 8382 (2015).
505 6. Petrova, N. *et al.* Ethnic Differences in the Frequency of CFTR
- 505 6. Petrova, N. *et al.* Ethnic Differences in the Frequency of CFTR Gene Mutations in
506 Populations of the European and North Caucasian Part of the Russian Federation. *Front* 506 Populations of the European and North Caucasian Part of the Russian Federation. *Front* **Generation**. *Front* **Generation**. *Gener* **12**, 678374 (2021).
- ⁵⁰⁷*Genet* **¹²**, 678374 (2021). 508 7. Schrijver, I. *et al*. The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients:
509 Implications for Molecular Diagnostic Testing. *J Mol Diagn* **18**, 39-50 (2016). 509 Implications for Molecular Diagnostic Testing. *J Mol Diagn* **18**, 39-50 (2016).
510 8. Palomaki, G.E., FitzSimmons, S.C. & Haddow, J.E. Clinical sensitivity of
- 510 8. Palomaki, G.E., FitzSimmons, S.C. & Haddow, J.E. Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic 511 screening for cystic fibrosis via CFTR carrier testing in a United States panethnic
512 population. Genet Med 6, 405-14 (2004). 512 population. *Genet Med* **6**, 405-14 (2004).
513 9. Shteinberg, M., Haq, I.J., Polineni, D. &
- ⁵¹³9. Shteinberg, M., Haq, I.J., Polineni, D. & Davies, J.C. Cystic fibrosis. *Lancet* **³⁹⁷**, 2195- 514 2211 (2021).
515 10. Stewart, C. &
- 515 10. Stewart, C. & Pepper, M.S. Cystic Fibrosis in the African Diaspora. *Ann Am Thorac Soc* 516 **14**, 1-7 (2017). 516 **14**, 1-7 (2017).
517 11. Quint, A., Lerg
- 517 11. Quint, A., Lerer, I., Sagi, M. & Abeliovich, D. Mutation spectrum in Jewish cystic
518 fibrosis patients in Israel: implication to carrier screening. Am J Med Genet A 136, 246-8 518 fibrosis patients in Israel: implication to carrier screening. *Am J Med Genet A* **136**, 246-8
519 (2005).
- 519 (2005).
520 12. Tian, X 520 12. Tian, X. *et al.* p.G970D is the most frequent CFTR mutation in Chinese patients with cystic fibrosis. *Human Genome Variation* 3, 15063 (2016). 521 cystic fibrosis. *Human Genome Variation* **3**, 15063 (2016).
522 13. Ni, Q. *et al.* Systematic estimation of cystic fibrosis preve
- 522 13. Ni, Q. *et al.* Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians. *Orphanet J Rare Dis* 17, 129 (2022). 523 spectrum comparison to Caucasians. *Orphanet J Rare Dis* 17, 129 (2022).
524 14. Levy, H. *et al.* Identification of molecular signatures of cystic fibrosis dise
- 524 14. Levy, H. *et al.* Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. *Physiol Genomics* 51, 27-41 (2019). 525 plasma-based functional genomics. *Physiol Genomics* **51**, 27-41 (2019).
526 15. Grosse, S.D. *et al.* Newborn screening for cystic fibrosis: evaluation of l
- 526 15. Grosse, S.D. *et al.* Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. *MMWR Recomm Rep* 53, 1-527 and recommendations for state newborn screening programs. *MMWR Recomm Rep* 53, 1-
528 36 (2004). 528 36 (2004).
529 16. Coverstone
- 529 16. Coverstone, A.M. & Ferkol, T.W. Early Diagnosis and Intervention in Cystic Fibrosis:
530 Imagining the Unimaginable. *Front Pediatr* 8, 608821 (2020). 530 Imagining the Unimaginable. *Front Pediatr* **8**, 608821 (2020).
531 17. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes fr
- 531 17. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed
532 Program. Nature 590, 290-299 (2021). 532 Program. *Nature* **590**, 290-299 (2021).
533 18. Moisan, S. *et al.* Analysis of long-ran
- 533 18. Moisan, S. *et al.* Analysis of long-range interactions in primary human cells identifies cooperative CFTR regulatory elements. *Nucleic Acids Research* 44, 2564-2576 (2015). 534 cooperative CFTR regulatory elements. *Nucleic Acids Research* 44, 2564-2576 (2015).
535 19. Backman, J.D. *et al.* Exome sequencing and analysis of 454,787 UK Biobar
- 535 19. Backman, J.D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628-634 (2021). 536 participants. *Nature* **599**, 628-634 (2021).
537 20. McLaren, W. *et al*. The Ensembl Variant I
- ⁵³⁷20. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **¹⁷**, 122 (2016).
- 538 21. Cingolani, P. *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster 539 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster
540 strain w1118: iso-2: iso-3. *Fly (Austin)* 6, 80-92 (2012). 540 strain w1118; iso-2; iso-3. *Fly (Austin)* **6**, 80-92 (2012).
541 22. Ideozu, J.E. *et al.* Increased Expression of Plasma-Inc
- 541 22. Ideozu, J.E. *et al.* Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic
542 Fibrosis. *Int J Mol Sci* 18(2017). 542 Fibrosis. *Int J Mol Sci* **18**(2017).
543 23. McKay, I.R. & Ooi, C.Y. The E
- 543 23. McKay, I.R. & Ooi, C.Y. The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR
544 Modulation: A Mini Review. *Front Pediatr* **10**, 914790 (2022). 544 Modulation: A Mini Review. *Front Pediatr* 10, 914790 (2022).
545 24. Albers, P.K. & McVean, G. Dating genomic variants and share
- 545 24. Albers, P.K. & McVean, G. Dating genomic variants and shared ancestry in population-
546 scale sequencing data. *PLoS Biol* 18. e3000586 (2020). ⁵⁴⁶scale sequencing data. *PLoS Biol* **¹⁸**, e3000586 (2020).

547 25. Denny, J.C. *et al.* The "All of Us" Research Program. *N Engl J Med* 381, 668-676 (2019).
548 26. Zhou, D., Bai, R. & Wang, L. The Cystic Fibrosis Transmembrane Conductance

- 548 26. Zhou, D., Bai, R. & Wang, L. The Cystic Fibrosis Transmembrane Conductance
549 Regulator 470 Met Allele Is Associated with an Increased Risk of Chronic Pancreatitis in 549 Regulator 470 Met Allele Is Associated with an Increased Risk of Chronic Pancreatitis in
550 Both Asian and Caucasian Populations: A Meta-Analysis. *Genetic Testing and Molecular* 550 Both Asian and Caucasian Populations: A Meta-Analysis. *Genetic Testing and Molecular Biomarkers* **24**, 24-32 (2020). ⁵⁵¹*Biomarkers* **²⁴**, 24-32 (2020).
- 552 27. Sun, Q. *et al.* Analyses of biomarker traits in diverse UK biobank participants identify
553 ssociations missed by European-centric analysis strategies. *J Hum Genet* 67, 87-93 553 ssociations missed by European-centric analysis strategies. *J Hum Genet* **67**, 87-93
554 (2022). 554 (2022).
555 28. Blancha
- 555 28. Blanchard, A.C. & Waters, V.J. Opportunistic pathogens in cystic fibrosis: epidemiology
556 and pathogenesis of lung infection. Journal of the Pediatric Infectious Diseases Society 556 and pathogenesis of lung infection. *Journal of the Pediatric Infectious Diseases Society*
557 **11**, S3-S12 (2022). 557 **11**, S3-S12 (2022).
558 29. Lima, E.d.S., Pezzin
- 558 29. Lima, E.d.S., Pezzin, L.S., Fensterseifer, A.C. & Pinto, L.A. Frequency of CFTR variants
559 in southern Brazil and indication for modulators therapy in patients with cystic fibrosis. 559 in southern Brazil and indication for modulators therapy in patients with cystic fibrosis.
560 *Genetics and Molecular Biology* 45(2021). ⁵⁶⁰*Genetics and Molecular Biology* **⁴⁵**(2021).
- 561 30. Erdoğan, M. *et al*. The Genetic Analysis of Cystic Fibrosis Patients with Seven Novel
562 Mutations in the CFTR Gene in the Central Anatolian Region of Turkey. *Balkan Medical* 562 Mutations in the CFTR Gene in the Central Anatolian Region of Turkey. *Balkan Medical Journal* 38, 357 (2021).
- ⁵⁶³*Journal* **³⁸**, 357 (2021). 564 31. Ortiz, S.C. *et al.* Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation. *Mol Genet Genomic Med* 5, 751-757 565 patients: the second report of the p.H609R mutation. *Mol Genet Genomic Med* **5**, 751-757
566 (2017). 566 (2017).
567 32. Sirvani.
- 567 32. Siryani, I. *et al.* Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine. *PLoS One* **10**, e0133890 ⁵⁶⁸(CFTR) Mutations in a Cohort of Patients Residing in Palestine. *PLoS One* **¹⁰**, e0133890
- 569 (2015).
570 33. Uppalur 570 33. Uppaluri, L., England, S.J. & Scanlin, T.F. Clinical evidence that V456A is a Cystic
571 Fibrosis causing mutation in South Asians. *J Cyst Fibros* 11, 312-5 (2012). 571 Fibrosis causing mutation in South Asians. *J Cyst Fibros* 11, 312-5 (2012).
572 34. Indika, N.L.R. *et al.* Phenotypic spectrum and genetic heterogeneity of cy
- 572 34. Indika, N.L.R. *et al.* Phenotypic spectrum and genetic heterogeneity of cystic fibrosis in
573 Sri Lanka. *BMC Medical Genetics* **20**, 89 (2019). 573 **Sri Lanka.** *BMC Medical Genetics* **20**, 89 (2019).
574 35. Deignan, J.L. *et al.* CFTR variant testing: a techni
- 574 35. Deignan, J.L. *et al.* CFTR variant testing: a technical standard of the American College of
575 Medical Genetics and Genomics (ACMG). *Genetics in Medicine* 22, 1288-1295 (2020). 575 Medical Genetics and Genomics (ACMG). *Genetics in Medicine* 22, 1288-1295 (2020).
576 36. Poolman, E.M. & Galvani, A.P. Evaluating candidate agents of selective pressure fo
- 576 36. Poolman, E.M. & Galvani, A.P. Evaluating candidate agents of selective pressure for cystic fibrosis. *J R Soc Interface* 4, 91-8 (2007). 577 cystic fibrosis. *J R Soc Interface* **4**, 91-8 (2007).
578 37. Morris, A.P., Whittaker, J.C. & Balding, D.J.
- 578 37. Morris, A.P., Whittaker, J.C. & Balding, D.J. Fine-scale mapping of disease loci via
579 shattered coalescent modeling of genealogies. Am J Hum Genet 70, 686-707 (2002). 579 shattered coalescent modeling of genealogies. *Am J Hum Genet* **70**, 686-707 (2002).
580 38. Slatkin, M. & Bertorelle, G. The use of intraallelic variability for testing neutrality
- 580 38. Slatkin, M. & Bertorelle, G. The use of intraallelic variability for testing neutrality and estimating population growth rate. Genetics **158**, 865-74 (2001). 581 estimating population growth rate. *Genetics* **158**, 865-74 (2001).
582 39. Yu, Y.C., Sohma, Y. & Hwang, T.C. On the mechanism of gati
- 582 39. Yu, Y.C., Sohma, Y. & Hwang, T.C. On the mechanism of gating defects caused by the
583 R117H mutation in cystic fibrosis transmembrane conductance regulator. *J Physiol* 594, 583 R117H mutation in cystic fibrosis transmembrane conductance regulator. *J Physiol* 594,
584 3227-44 (2016). 584 3227-44 (2016).
585 40. Castellani, C. *et*
- 585 40. Castellani, C. *et al.* Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros* 7, 179-96 (2008). 586 analysis in clinical practice. *J Cyst Fibros* 7, 179-96 (2008).
587 41. Sagesse, G.J., Yadava, S. & Mandava, A. Atypical Cystic F
- 587 41. Sagesse, G.J., Yadava, S. & Mandava, A. Atypical Cystic Fibrosis: Diagnosis at the Age of 57 Years. Cureus 12, e10863 (2020). 588 of 57 Years. *Cureus* **12**, e10863 (2020).
589 42. De Wachter, E., Thomas, M., Wanyama
- 589 42. De Wachter, E., Thomas, M., Wanyama, S.S., Seneca, S. & Malfroot, A. What can the CF registry tell us about rare CFTR-mutations? A Belgian study. *Orphanet Journal of* 590 CF registry tell us about rare CFTR-mutations? A Belgian study. *Orphanet Journal of* 591 *Rare Diseases* 12, 142 (2017). ⁵⁹¹*Rare Diseases* **¹²**, 142 (2017).
-

594

-
- 595
596
- 597
- 598
- 598
- 600
- 601
- 602

602 ⁶⁰³**Table 1. Diversity of** *CFTR* **variants across ancestries**

605 ⁶⁰⁵**Table 2. Number of participants with CF-causing variants across ancestries**

606

607
608

⁶⁰⁸**Table 3. Participants with two CF-causing variants**

609

÷,

l,

- – –
613

Fig. 1: Most *CFTR* **variants are intronic**

Variant types and consequences

Several variant types with varying consequences were identified in the *CFTR* gene. The labels in the chart represent the number and percentage of the Intronic variants (highlighted in orange) clearly dominated over half of the captured variants despite Whole Exome Sequencing technology capturing mostly exomes.

Fig. 2: Ancestry-specific variants characterized

Intersection of *CFTR* **variants across ancestries**

A) Graph of total number of variants (x-axis; Set Size) detected in each ancestry (y-axis). **B)** Intersection of variants detected across the ancestries. Each column corresponds to the number of variants in each intersection. Ancestries present in each intersection are represented by the black dots. Intersections with single dots represents ancestry-specific variants. **C)** A list of ancestry-specific variants. The highest number of unique *CFTR* variants (2212/3192) was detected in Europeans.

Fig. 3: Common CF-causing variants in each ancestry represented in pie charts

Common CF-causing variants across ancestries

For each ancestry, slices vary by color, with blue representing the most abundant CF-causing variant. F508del was the most common CF-causing variant detected in all ancestries, except for East Asia where V520F was the most common.

Fig. 4: Ancestry-specific CF-causing variants characterized

Intersection of CF-causing variants across ancestries

A) Graph of total number of variants (x-axis; Set Size) detected in each ancestry (y-axis)**. B)** Intersection of variants detected across the ancestries**.** Each column corresponds to the number of variants in each intersection. Ancestries present in each intersection are represented by the black dots. Intersections with single dots represents ancestry-specific CF-causing variants. **C)** A list of ancestry-specific CF-causing variants. The highest number of unique CF-causing variants (n=50) was detected in Europeans.

A) Enriched phenotypes observed in patients with two CF-causing variants **B)** Enriched phenotypes observed in patients with one CF-causing and a high impact variant. The top 10 enriched phenotypes are represented in bar graphs. The negative logarithm of the Bonferroni adjusted p-value was used to deduce the enrichment scores shown in the bars. Enrichment score >1.3 corresponds to a significance threshold of $p<0.05$.